News & Analysis as of

Capital Raising › Investors › Life Sciences

Cooley LLP

Deal Count Increases and Invested Capital Down for Late-Stage Rounds; Valuations Rise and Pay-to-Play Reaches 10.1%

Cooley LLP on

Cooley handled 238 reported venture capital financings in Q2 2025, representing $6.5 billion of invested capital. Deal count increased by more than 20% across all stages of financing compared to the previous quarter, with...more

Fenwick & West LLP

Clinical Data FAQs: How to Approach Fundraising and Investor Relations

Fenwick & West LLP on

For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword....more

McDermott Will & Schulte

Key Takeaways | Alternative Capital-Raising Strategies in Challenging Times

McDermott Will & Schulte on

During this session, the panelists shared alternative capital-raising financing strategies, including venture capital (VC), accelerators, spin-outs, bridge financing, licensing, and government agency support. They also...more

McDermott Will & Schulte

[Event] Life Sciences Dealmaking Symposium - November 9th, Boston, MA

McDermott Will & Schulte on

Please join McDermott for our highly anticipated Life Sciences Dealmaking Symposium! Now in its 12th year, the Symposium offers a unique platform for education, insight sharing, purposeful networking and strategic...more

Latham & Watkins LLP

5 Tips for Navigating PIPEs in the European Life Sciences Sector

Latham & Watkins LLP on

The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity. Small- and mid-cap life sciences companies typically...more

Fenwick & West LLP

Navigating Uncertain Times: IPO Insights for Late-Stage Technology and Life Sciences Companies - 2023

Fenwick & West LLP on

After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more

Goodwin

European Life Sciences Deals Trends

Goodwin on

In Europe, life sciences deals increased over the last few years with strong acceleration in 2021. As a result, the market wonders whether this is just an uptick or rather a steady trend which will impact our market in the...more

Rothwell, Figg, Ernst & Manbeck, P.C.

Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes

Rothwell, Figg, Ernst & Manbeck, P.C. on

On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing, co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital...more

Arnall Golden Gregory LLP

[Webinar] Money, Money, Money: Raising Capital and Exit Transactions for Life Sciences Companies - October 3rd, 12:00 pm ET

Arnall Golden Gregory LLP on

Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide